News
ARVN
33.45
+0.03%
0.01
Multiple Insiders Sold Arvinas Shares Presenting Weak Signs For Investors
Arvinas, Inc. Insiders sold US$485k worth of shares in the last year. The biggest insider sale was by John Houston for US$244k. In the last 12 months, Arvinas insiders didn't buy any shares. The company has a 1.9% of the company. But the company has seen significant insider selling over the last three months. It's important to keep in mind Arvin as an company to watch.
Simply Wall St · 17h ago
Analysts’ Top Healthcare Picks: Quanterix (QTRX), Intuitive Surgical (ISRG)
TipRanks · 2d ago
Arvinas Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
Arvinas Price Target Cut to $87.00/Share From $90.00 by HC Wainwright & Co.
Dow Jones · 3d ago
Weekly Report: what happened at ARVN last week (0408-0412)?
Weekly Report · 3d ago
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
NASDAQ · 6d ago
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
TipRanks · 6d ago
Arvinas Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $87
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
TipRanks · 6d ago
ARVINAS, INC. <ARVN.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $87 FROM $90
Reuters · 6d ago
Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
Arvinas and Novartis partnering on prostate cancer protein degrader is a win-win situation for both parties. Arvinas's shares are up more than 75% since November 2023. The biotech's lead asset, vepdegestrant, is being developed in partnership with Pfizer for breast cancer studies.
Seeking Alpha · 04/11 19:50
BUZZ-U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
The Dow Jones Industrial Average was up 0.02% on Thursday. The benchmark S&P 500 and the Dow were muted as long-dated Treasury yields remained elevated. Rent the Runway, Lumen Technologies, Enliven Therapeutics were among the top stocks on the NYSE.
Reuters · 04/11 18:05
Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential
TipRanks · 04/11 17:05
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
The benchmark S&P 500 and the Nasdaq gained on Thursday. Producer prices data soothed investor jitters about sticky inflation. The Dow Jones Industrial Average was down 0.36% in the morning. Constellation Brands, Nike, Rocket Lab and Domino's Pizza are among the stocks on the move.
Reuters · 04/11 16:07
ARVINAS INC <ARVN.O>: WEDBUSH CUTS TARGET PRICE TO $57 FROM $59
Reuters · 04/11 14:49
BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Devon Energy, Arvinas
DoorDash, Devon Energy, Arvinas among top Nasdaq percentage gainers. Softer-than-anticipated producer prices data soothed investor fears about sticky inflation. Dow e-minis were up 0.08% in premarket trading. The Nasdaq eyed a higher open on Thursday.
Reuters · 04/11 13:39
ARVINAS SHARES UP 6.1% CO ENTERS INTO GLOBAL LICENSE AGREEMENT WITH NOVARTIS FOR PROSTATE CANCER DRUG
Reuters · 04/11 13:33
UPDATE 1-Novartis licenses Arvinas' cancer drug for up to $1 billion
Novartis licenses Arvinas' cancer drug for up to $1 billion. Swiss drugmaker to gain access to experimental prostate cancer drug. Novartis has acquired global rights to develop and commercialize the drug, ARV-766. The drug is designed to target and degrade androgen receptors.
Reuters · 04/11 11:40
More
Webull provides a variety of real-time ARVN stock news. You can receive the latest news about Arvinas through multiple platforms. This information may help you make smarter investment decisions.
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.